ArticleInternational journal of preventive medicine2020
Article in International journal of preventive medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA
methodsMale ICR mice were randomly divided into normal control, APAP, APAP + Sm (silymarin) and APAP + CLC (0.2%, 0.5% and 1%) groups. The glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), Albumin, and BUN plasma activities were detected using blood biochemistry assay. The hepatic tissue GOT, GPT, superoxide dismutase (SOD) and catalase (CAT) activity were also detected. Lipid peroxidation, MDA, protein expression levels were examined.
resultsThe results showed that the 1% CLC supplementation group and Silymarin (Sm) could significantly alleviate increased serum GOT, GPT and BUN, and the decreased serum Albumin. At the same time, the increased hepatic tissue GOT and GPT activities were alleviated as well as MDA. Enhanced SOD and CAT protein expression levels were increased in APAP-induced liver injury. Lipofuscin and hepatic veins cups disappeared in the Sm and 1% CLC supplementation groups shown with H&E staining.
conclusionsTherefore, CLC probably could develop hepatoprotective products against chemical-induced liver damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.